Loading...
•
Sep 30, 2022
Inozyme Q3 2022 Earnings Report
Inozyme reported financial results for Q3 2022 and provided business updates.
Key Takeaways
Inozyme Pharma reported a net loss of $16.4 million for the third quarter of 2022. The company's cash, cash equivalents, and investments were $141.5 million as of September 30, 2022, which is expected to fund cash flow requirements into the second quarter of 2024.
Topline data from Phase 1/2 clinical trial of INZ-701 in ENPP1 Deficiency on track for the fourth quarter of 2022.
Topline data from Phase 1/2 clinical trial of INZ-701 in ABCC6 Deficiency on track for the first quarter of 2023.
Dosing is underway in the third dose cohort of both trials.
Cash, cash equivalents, and investments were $141.5 million as of September 30, 2022.
Forward Guidance
Based on its current plans, the Company expects that its cash, cash equivalents, and investments together with the remainder of the first tranche of its debt facility as of September 30, 2022 will enable the Company to fund its cash flow requirements into the second quarter of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...